All In Biotech

NDA 021644 · Galderma Labs

Clobex

Clobetasol Propionate · Topical

Last checked: Nov 19, 2026Latest source record: Nov 30, 2012 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Feb 5, 2004

Approved uses

1

Original approval plus efficacy supplements

Registered trials

119

23 Phase 3, 10 recruiting

FAERS reports

10,595

4,972 serious, 439 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 16, 2023.

Clobetasol Propionate Shampoo, 0.05% is a corticosteroid indicated for the treatment of moderate to severe scalp psoriasis in subjects 18 years of age and older. ( 1 ) Limitations of Use: Do not use on the face, axillae or groin. ( 1.2 ) Avoid any contact with the eyes and lips. ( 1.2 ) 1.1 Indication Clobetasol Propionate Shampoo, 0.05%, is a super-high potent topical corticosteroid formulation indicated for the treatment of moderate to severe forms of scalp psoriasis in subjects 18 years of age and older. Treatment should be limited to 4 consecutive weeks. The total dosage should not exceed 50 g (50 mL or 1.75 fl. oz.) per week. Patients should be instructed to use Clobetasol Propionate Shampoo, 0.05%, for the minimum time period necessary to achieve the desired results [ see Dosage and Administration ( 2 ) ]. Use in patients younger than 18 years of age is not recommended due to numerically high rates of hypothalamic-pituitary-adrenal (HPA) axis suppression [ see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.4 ) ]. 1.2 Limitations of Use Clobetasol Propionate Shampoo, 0.05%, should not be used on the face, groin or axillae. Avoid any contact of the drug product with the eyes and lips. In case of contact, rinse thoroughly with water all parts of the body that came in contact with the shampoo.

Mechanism: Like other topical corticosteroids, Clobetasol Propionate Shampoo, 0.05%, has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • CLOBEX · CLOBETASOL PROPIONATE 0.05% · SHAMPOO, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Clobetasol Propionate" as an intervention, any sponsor and status, largest first.

All 119 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,087
  • pruritus983
  • off label use682
  • rash676
  • product use in unapproved indication553
  • psoriasis550
  • fatigue531
  • headache501
  • diarrhoea448
  • nausea441
  • dry skin423
  • arthralgia421

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200417
200520
200658
200792
200895
2009125
2010135
2011215
2012318
2013162
2014185
2015346
2016403
2017536
2018459
2019471
2020558
2021604
2022920
20231,216
20241,152
20251,320
20261,188

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Clobex (Clobetasol Propionate)

2024 spending

$46K

Beneficiaries

19

46 claims

Per beneficiary

$2,440

$6.66 per unit

View as table
YearSpending
2020$685,024
2021$372,701
2022$148,368
2023$134,516
2024$46,352

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 257 on PubMed

Sponsor: Galderma Labs

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.